TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 51 filers reported holding TCR2 THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 20.14 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $205,829 | -5.7% | 137,219 | -37.2% | 0.00% | – |
| Q4 2022 | $218,376 | +10.9% | 218,638 | +100.0% | 0.00% | – |
| Q3 2022 | $197,000 | -37.9% | 109,319 | 0.0% | 0.00% | – |
| Q2 2022 | $317,000 | -78.0% | 109,319 | -79.1% | 0.00% | – |
| Q1 2022 | $1,444,000 | -39.9% | 523,157 | +1.5% | 0.00% | – |
| Q4 2021 | $2,401,000 | -81.4% | 515,189 | -66.0% | 0.00% | -100.0% |
| Q3 2021 | $12,890,000 | -64.8% | 1,514,717 | -32.1% | 0.00% | -50.0% |
| Q2 2021 | $36,614,000 | -24.2% | 2,231,224 | +2.0% | 0.00% | -33.3% |
| Q1 2021 | $48,319,000 | +59.9% | 2,188,354 | +124.0% | 0.00% | +50.0% |
| Q4 2020 | $30,220,000 | +316.0% | 977,060 | +173.3% | 0.00% | – |
| Q3 2020 | $7,264,000 | +82.8% | 357,463 | +38.2% | 0.00% | – |
| Q2 2020 | $3,973,000 | +152.7% | 258,683 | +27.3% | 0.00% | – |
| Q1 2020 | $1,572,000 | -45.9% | 203,155 | -0.1% | 0.00% | – |
| Q4 2019 | $2,904,000 | +15.9% | 203,352 | +22.0% | 0.00% | – |
| Q3 2019 | $2,505,000 | +1548.0% | 166,634 | +1033.6% | 0.00% | – |
| Q2 2019 | $152,000 | – | 14,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $11,748,000 | 4.96% |
| MPM BioImpact LLC | 3,370,982 | $9,776,000 | 2.72% |
| TANG CAPITAL MANAGEMENT LLC | 3,641,606 | $10,561,000 | 1.60% |
| Newtyn Management, LLC | 692,799 | $2,009,000 | 0.38% |
| K2 PRINCIPAL FUND, L.P. | 1,078,070 | $3,126,000 | 0.34% |
| HARBOR CAPITAL ADVISORS, INC. | 64,341 | $187,000 | 0.14% |
| Redmile Group, LLC | 1,094,645 | $3,174,000 | 0.12% |
| Artal Group S.A. | 750,000 | $2,175,000 | 0.12% |
| Oasis Management Co Ltd. | 200,000 | $580,000 | 0.10% |
| X-Square Capital, LLC | 31,919 | $93,000 | 0.06% |